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Abstract
Background: The novel coronavirus pandemic calls for a rapid adaptation of conventional medical practices to
meet the evolving needs of such vulnerable patients. People with coronavirus disease (COVID-19) may frequently
require treatment with psychotropic medications, but are at the same time at higher risk for safety issues because
of the complex underlying medical condition and the potential interaction with medical treatments.
Methods: In order to produce evidence-based practical recommendations on the optimal management of
psychotropic medications in people with COVID-19, an international, multi-disciplinary working group was
established. The methodology of the WHO Rapid Advice Guidelines in the context of a public health emergency
and the principles of the AGREE statement were followed. Available evidence informing on the risk of respiratory,
cardiovascular, infective, hemostatic, and consciousness alterations related to the use of psychotropic medications,
and drug–drug interactions between psychotropic and medical treatments used in people with COVID-19, was
reviewed and discussed by the working group.
Results: All classes of psychotropic medications showed potentially relevant safety risks for people with COVID-19.
A set of practical recommendations was drawn in order to inform frontline clinicians on the assessment of the
anticipated risk of psychotropic-related unfavorable events, and the possible actions to take in order to effectively
manage this risk, such as when it is appropriate to avoid, withdraw, switch, or adjust the dose of the medication.
Conclusions: The present evidence-based recommendations will improve the quality of psychiatric care in people
with COVID-19, allowing an appropriate management of the medical condition without worsening the psychiatric
condition and vice versa.
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Background
The novel coronavirus outbreak is a global health emer-
gency calling for a rapid adaptation of conventional clin-
ical practices in many medical areas, including
psychiatry. Coronavirus disease (COVID-19) is a sys-
temic infection potentially targeting multiple organs and
functions. Interstitial pneumonia is the landmark feature
of this condition, leading to severe respiratory distress
requiring intensive life support in about one out of
twenty symptomatic cases [1, 2]. Old age and pre-
existing medical comorbidities are associated with in-
creased severity and mortality [3].
Although there is debate about the efficacy and safety
of medical treatments to prevent complications and de-
crease mortality [4], current clinical protocols generally
include the off-label use of chloroquine, hydroxychloro-
quine, antiviral medications, anticoagulant prophylaxis,
and immune system modulators (e.g., interferons) [5–7].
People with COVID-19 may frequently experience a
new onset or exacerbation of psychiatric manifestations
in response to the communication of the diagnosis, the
need for forced isolation, the presence of severely dis-
tressing medical symptoms, and the possible risk of
death. In addition, intensive care support and experi-
mental medical treatments with psychiatric side effects
(e.g., antimalarials) might be an additional risk factor for
the onset psychiatric symptoms and altered states of
consciousness, including delirium [8, 9]. Epidemiologic
data, although preliminary, showed that up to one of
four patients might experience symptoms of anxiety or
depression [10] and about 15% might develop impaired
consciousness states [11], which is likely to be associated
with a remarkable increased risk of death [12].
For these reasons, people with COVID-19 may require
treatment with medications targeting psychiatric mani-
festations. As in the general population these medica-
tions are associated with a wide range of safety concerns,
in people with COVID-19, their use may be particularly
challenging. Psychotropic medications may interact with
the medical treatments for COVID-19, and some of their
adverse effects may worsen the course and outcome of
the underlying medical condition. In this context, the
aim of this evidence review and practical recommenda-
tions is to make frontline doctors (including psychia-
trists, other specialists, and general practitioners) aware
of clinically relevant safety issues of psychotropic medi-
cation use in people with COVID-19 and possible man-
agement strategies.
Methods
The process of evidence retrieval, appraisal, and discus-
sion followed the methodology of the World Health
Organization (WHO) Rapid Advice Guidelines in the
context of a public health emergency [13]. Details of the
process are reported in Additional File 1 [3, 10–97]. Re-
sults were reported following the AGREE statement [14].
A multi-disciplinary international working group was
established ad hoc. Professionals with expertise in re-
search methodology, guideline development, epidemi-
ology, consultation-liaison psychiatry, and clinical
psychopharmacology were involved (see Additional File
1: Table S1). Potentially relevant financial and intellec-
tual interests were publicly disclosed in advance and in-
dependently assessed by all members, in order to
minimize potential biases. On the basis of a shared
process directly involving all members, the following key
clinical elements were considered of utmost priority in
terms of potential safety issues of psychotropic medica-
tions in people with COVID-19: (a) drug–drug interac-
tions, (b) respiratory risk, (c) cardiovascular risk, (d) risk
of infections, (e) coagulation risk, and (f) risk of delir-
ium. The following classes of psychotropic medications,
as defined by the Anatomical Therapeutic Chemical
(ATC) classification system, were included: antidepres-
sants, anxiolytics, antipsychotics, and selected antiepilep-
tics employed for the treatment of mood disorders.
A literature search, last updated on the 8 May 2020,
was conducted using PubMed, Web of Science Core
Collection, and the Cochrane Database of Systematic Re-
views. Terms describing psychotropic medications were
combined with terms describing the key clinical ele-
ments identified. The search was limited to up-to-date
systematic reviews published in the last 10 years. Priority
was given to systematic reviews reporting a quantitative
synthesis of safety outcomes of psychotropic medications
in the general population or, if available, in people with
medical conditions or vulnerabilities similar to those of
COVID-19: respiratory diseases, cardiovascular diseases,
and elderly patients. Both in- and outpatient settings
were considered (see Additional File 1: Tables S2 and
S3). The search output was screened and selected by one
review author (DP) and independently checked for ac-
curacy by two other review authors (GO, CB). Informa-
tion on population, intervention, comparison, and
outcomes of interest was extracted from the included
systematic reviews, and a narrative synthesis was devel-
oped to support the working group discussion. Meth-
odological quality of the included systematic reviews was
assessed using AMSTAR-2 to aid interpretation of the
results, while the certainty of evidence according to the
GRADE methodology was not assessed.
Information on drug–drug pharmacokinetic and phar-
macodynamic interactions between psychotropic medi-
cations and medical treatments for COVID-19 was
searched by cross-checking four drug–drug interaction
databases (namely the Food and Drug Administration
(FDA) database, MediQ, PSIAC, and the COVID-19
database of the Liverpool University) [98–101] and the
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European Medicines Agency (EMA) and FDA-registered
product characteristics [34, 102]. Additionally, PubMed
was searched using the heading “drug interactions” com-
bined with names of individual psychotropic medications
and selecting only human studies performed in the last
5 years. When different sources provided a different esti-
mate of the expected severity of an interaction, we used
a conservative approach by reporting the most severe
scenario. Evidence from pharmacokinetics simulations
were not considered, as they might not apply to real-
world patients [103]. The anti-COVID-19 medications
considered included those routinely used off-label in
current clinical practice protocols [6], and those cur-
rently undergoing rigorous experimental protocol, as re-
ported by the WHO [7]. Drug–drug interactions were
organized in a tabular layout and classified in four de-
grees of severity: (a) high risk, if a relevant clinical im-
pact is likely as available evidence indicate strong
inhibition or induction of the major metabolic pathways
of medications, well-established adverse reactions related
to drug–drug interactions, and if there are contraindica-
tions according to the package inserts; (b) moderate risk,
if a relevant clinical impact is less likely according to the
evidence, but cannot be excluded; (c) low risk, if a rele-
vant clinical impact is unlikely according to the evi-
dence; (d) very low risk, if the evidence indicate that no
relevant clinical impact is expected.
All members of the working group individually
reviewed the narrative synthesis of the literature and the
tabular synthesis of drug–drug interactions, and subse-
quently, collegial discussions were organized electronic-
ally. The discussion was moderated in order to appraise
the available evidence in light of possible values and
preferences, clinical expertise considerations, certainty of
the evidence retrieve, and feasibility issues, according to
the GRADE Evidence-to-Decision Framework [104]. Fol-
lowing discussion, the working group formulated prac-
tical recommendations for clinicians. In case of
disagreements, a vote was taken. Agreement by ≥ 80% of
experts was required for a clinical statement to be
retained. Considering the rapid process employed, no
external review was performed.
Results
The literature search provided 1531 hits. After duplicate
removal and screening of title and abstract, 113 articles
were retained for full inspection. Finally, 10 systematic
reviews providing a quantitative synthesis on the out-
comes of interest were selected, and 64 articles included
as additional material (see Additional File 1: Fig. S1; Ta-
bles S4, S5 and S6). Data were extracted and synthesized
by the scientific secretariat in order to inform the discus-
sion of the working group. The extended version of the
evidence synthesis is available in Additional File 1.
Table 1 shows the included systematic reviews, the out-
comes extracted, and their quality according to the
AMSTAR-2 checklist (see also Additional File 1: Table
S7). In terms of populations, we found relatively limited
evidence on medical conditions comparable to COVID-
19, while most evidence was on safety outcomes of psy-
chotropic medications in the general population.
Synthesis of the evidence
Drug–drug interactions
In patients with COVID-19, the risks of drug–drug in-
teractions involving psychotropic medications might be
relevant. Firstly, the bioavailability and disposition of
several psychotropic medications might be importantly
affected by COVID-19-related systemic inflammation
processes [65], impaired liver functioning [35], and
abrupt smoking cessation [45, 46, 64]. Secondly, psycho-
tropic medications and medical treatments can recipro-
cally affect each other’s plasma levels by inducing or
inhibiting cytochrome P450 (CYP) activity to an extent
which is poorly understood and hardly predictable [37].
Thirdly, these combinations are at risk of pharmacody-
namic interactions, and particularly QTc prolongation,
immunity, and coagulation abnormalities. Pharmacoki-
netic and pharmacodynamic interactions for a selection
of psychotropic medications, and indications for their
management, are synthetically reported in Table 2, while
a detailed table extensively reporting all psychotropic
medications is available in Additional File 1: Table S8.
Respiratory risk
COVID-19-related bilateral interstitial pneumonia is as-
sociated with hypoxic respiratory distress and can rap-
idly evolve into a full-blown acute respiratory distress
syndrome (ARDS) [106], which is the major cause of
death in people with COVID-19 [29, 106].
Data from randomized trials on antidepressants did
not show an increased risk of respiratory distress and
overall mortality in patients with COPD (including eld-
erly patients) exposed to selective serotonin reuptake in-
hibitors (SSRIs) and tricyclic antidepressants (TCAs)
[72] and authoritative guidelines indicate SSRIs as a safe
choice in people with medical conditions (including re-
spiratory disease) [67]. However, data from a recent,
large observational study showed a higher risk for COPD
worsening or COPD-related hospitalization and mortal-
ity in older patients taking SSRIs and SNRIs versus those
not exposed [89].
Antipsychotics are associated with an increased risk of
respiratory, thoracic, and mediastinal serious adverse
events according to data from randomized trials [78]
(Table 1). The risk of respiratory distress is probably
higher for highly sedative agents, particularly at higher
doses, in combination, and when they are prescribed in
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Table 1 Systematic reviews reporting a quantitative synthesis of the evidence for the outcomes selected by the working group
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Table 1 Systematic reviews reporting a quantitative synthesis of the evidence for the outcomes selected by the working group
(Continued)
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patients with pre-existing respiratory impairment [39,
90]. In case of psychomotor agitation requiring rapid
tranquilization with antipsychotics (e.g., hyperkinetic de-
lirium), the risk for acute extrapyramidal symptoms (e.g.,
dystonia, with possible impaired swallowing and conse-
quent risk of aspiration) and reduced mobility can not-
ably worsen respiratory distress [80, 107].
Mood stabilizers have mild-to-moderate sedative pro-
files, and there is no evidence of a relevant risk for ex-
cessive sedation and related respiratory distress [24, 66].
Although the risk of respiratory suppression with benzo-
diazepines is notably lower than barbiturates or other
neuromuscular blocking agents [21, 50, 52], it may be rele-
vantly high in people with acute respiratory distress and in
the elderly [33, 42, 80, 88]. The risk of respiratory distress
is related to the differential sedative properties of different
agents, their half-life, and is usually dose-dependent [33,
41, 49, 88]. Data from randomized trials showed no rele-
vant impact on respiratory outcomes in people with
chronic obstructive pulmonary disease (COPD) treated
Table 1 Systematic reviews reporting a quantitative synthesis of the evidence for the outcomes selected by the working group
(Continued)
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8168) emerged for olanzapine
(OR 0.25; 95% CI 0.09 to 0.69)
and risperidone (OR 0.27; 95%
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differences emerged for
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1.30 to 6.80).
Low
AD antidepressant, AP antipsychotic, CE credibility-of-evidence classification (I = convincing evidence; II = highly suggestive evidence; III = suggestive evidence; IV =
weak evidence), CI confidence interval, FEV forced expiratory volume, FGA first-generation antipsychotic, ICU intensive care unit, MA meta-analysis, MD mean
difference, N number of studies included in the analysis, n number of participants included in the analysis, OR odds ratio, RCT randomized controlled trial, SGA
second-generation antipsychotic, SR systematic review, RR risk ratio, SNRI serotonin–norepinephrine reuptake inhibitors, SSRI selective serotonin reuptake inhibitor,
TCA tricyclic antidepressant, VTE venous thromboembolism
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with benzodiazepines for insomnia, although the pooled
sample size was relatively small (Table 1) [59].
Cardiovascular risk
People with COVID-19 may have several cardiovascular
risk factors, including (a) old age; (b) pre-existing co-
morbid cardiovascular diseases; (c) use of medical treat-
ments with QTc-prolonging properties, often in
combination (e.g., antivirals, chloroquine/hydroxychloro-
quine and antibiotics); (d) a possible direct cardiotoxic
effects of the coronavirus; and (e) electrolyte alterations
related to abnormal respiratory gas exchange [3, 20, 87,
92, 97]. The most important risk factors of severe ar-
rhythmias, such as torsade de pointes, include the mag-
nitude of QTc prolongation, pre-existing heart disease,
female sex, bradycardia, hypokalemia, and other electro-
lyte abnormalities [44].
Data from randomized studies in people with ischemic
heart disease did not show an increased risk of cardio-
vascular mortality and nonfatal cardiac events for antide-
pressants (particularly SSRIs) [105]. On the other hand,
data from observational studies showed an increased risk
of coronary heart disease for tricyclic antidepressants
(TCAs), but not SSRIs and antidepressants as a class,
while SSRIs but not TCAs were associated with an in-
creased risk for cerebrovascular disease [30] (Table 1).
Tricyclic antidepressants and, to a lesser extent, citalo-
pram, escitalopram, and venlafaxine have been associated
with QTc prolongation, with a possibly higher risk in
older patients [44, 75].
Antipsychotics have been shown to be associated with
serious cardiovascular events according to data from ob-
servational studies assessing sudden cardiac death, myo-
cardial infarction, and stroke [70], while data from
randomized trials confirmed an increased risk of QTc
prolongation for a number of antipsychotics [48], but
not a higher risk of serious cardiac and vascular adverse
events [78] (Table 1). Antipsychotic combination and
higher cumulative doses might contribute to QTc pro-
longation [18, 85]. The differential risk of QTc prolonga-
tion of antipsychotics is not entirely consistent across
different data sources and study designs [44, 48]. In gen-
eral, the risk of QTc prolongation should not be
neglected for any antipsychotic [44, 71], although its pre-
dictive proprieties on TdP are still unclear [79].
The risk of arrhythmias is probably very low for mood
stabilizers and benzodiazepines [50, 66], with the pos-
sible exception of lithium, for which benign electrocar-
diographic changes and cases of ventricular arrhythmia
and sudden cardiac death have been described [34, 61].
Risk of infections
Systemic dysregulation of immunity and inflammation re-
sponse is a key feature of COVID-19. The severity of in-
flammatory parameters (such as IL-6) has been associated
with the fatality risk [62, 74], and immunosuppressive
Table 2 Clinical risk and actions recommended for selected drug–drug interactions between psychotropic and medical treatments
for COVID-19
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therapies may play a role in treatment and prevention of
complications [63].
Antidepressants have been consistently shown to have
anti-inflammatory proprieties, although little is known
about their possible role in systemic infections [38, 54,
84]. In vitro studies showed a protective effect against bac-
teria and fungi [26], but clinical data are unclear, as a pos-
sibly higher risk of Clostridium difficile infection has been
reported [47]. Tricyclic antidepressants, and particularly
clomipramine and imipramine, have been associated with
possible blood dyscrasias, including neutropenia [58].
Antipsychotics have been associated with immunosup-
pressive proprieties, such as decreased pro-inflammatory
cytokine levels, blood dyscrasias, and altered production
of antibodies [60, 73, 76, 77]. The risk of neutropenia is
about 1% for clozapine (3% in the elderly) and 0.1% for
phenothiazines [36], while for other medications data
are sparse [68]. Furthermore, both first- and second-
generation antipsychotics have been associated with a
higher risk of pneumonia in observational studies [32].
Data from randomized trials including mostly second-
generation antipsychotics showed a higher risk of infec-
tions [78] (Table 1). Apart from immunity abnormalities
[82], multiple mechanisms may contribute, including re-
duced clearance of the airways (related to central sed-
ation and inhibition of cough), impaired chest
movements and swallowing due to extrapyramidal symp-
toms, and sialorrea [51]. This risk might be particularly
relevant for clozapine [27].
Carbamazepine, oxcarbazepine, and, to a lesser extent,
sodium valproate, have been associated with an in-
creased risk of neutropenia, while lithium appears to be
free from relevant immunological effects [66].
Data from observational studies showed an increased
risk of pneumonia for benzodiazepines as compared to
non-users for both older and younger patients, short-
term and long-term use, short- and long-term acting
agents, and current and recent users [83] (Table 1).
Coagulation risk
Blood hypercoagulability related to inflammatory endo-
thelial dysfunction has been largely reported in patients
with COVID-19, ranging from mild manifestations to
life-threatening conditions, such as disseminated intra-
vascular coagulation [29, 31]. Low molecular weight
heparin has been suggested as an effective prophylaxis
since early stages of the disease [22].
Antidepressants have been associated with various
hemostasis alterations [43]. Observational studies shown
an increased risk of severe bleeding at different sites has
been shown for SSRIs and serotonin–norepinephrine re-
uptake inhibitors (SNRIs) [30] and an increased risk of
thromboembolism for all antidepressant classes [55].
The risk of bleeding is arguably higher in vulnerable
patients (e.g., old age, pre-existing coagulation abnor-
malities, anticoagulant therapy, major surgery) [16, 57].
Antipsychotics have been clearly shown to be associ-
ated with an increased risk of thromboembolism in large
observational studies, with an arguably higher risk in
vulnerable populations with pre-existing risk factors [70]
(Table 1). It is still uncertain if there are relevant differ-
ences in risk between individual agents [108].
The risk for pro- or anticoagulant effect is likely to be
low for mood stabilizers and benzodiazepines [34].
Risk of delirium
Although epidemiological data are preliminary, delirium
has been frequently described in people with COVID-19
[11] and is associated with unfavorable prognosis [12].
Old age, medical comorbidities, dementia, and multiple
pharmacological treatments are well-known risk factors
for both delirium and COVID-19 severity [3, 91]. Neuro-
tropic mechanisms of COVID-19 have been also hypoth-
esized [17]. Furthermore, many of the experimental
medical treatments use for COVID-19 have a well-
known risk for neuropsychiatric side effects (e.g., anti-
malarial and antiviral medications, interferons, cortico-
steroids) and may represent an additional risk. Some
psychotropic medications are also known as risk factors
for delirium. In particular, benzodiazepines, antidepres-
sants with anticholinergic proprieties (mainly TCAs, but
possibly also paroxetine), and lithium are considered at
high risk according to data from observational studies
[23] (Table 1). Anticholinergic medications are often a
precipitating factor and are associated with delirium se-
verity. It has been estimated that medications alone
might account for up to 40% of cases of delirium [15,
23]. Data from a recent meta-analysis of randomized tri-
als showed that olanzapine and risperidone were effect-
ive in preventing delirium as compared to placebo or
treatment as usual, while midazolam increased its inci-
dence [95] (Table 1).
Evidence-based practical recommendations
Based on the considerations reported above and after
collegial discussion, and taking into consideration values,
feasibility, resource use, and certainty of the evidence ac-
cording to the Evidence-to-Decision framework (see
Additional File 1: Table S9), the following practical rec-
ommendations were formulated:
1. The risk and severity of drug–drug
pharmacokinetic and pharmacodynamic
interactions between COVID-19 medical treatments
and psychotropic medications should always be
assessed, taking into account the additional vulner-
ability related to the underlying medical condition
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(e.g., cardiovascular conditions increasing the risk of
QTc prolongation).
2. In case of high-risk interactions, the combination
should be avoided if possible. In case of moderate-
risk interactions, dose adjustments, psychotropic
medication withdrawal, or switch to a safer medica-
tion should be considered. In case of low-risk inter-
actions, regular monitoring should be provided,
with dose adjustments as clinically appropriate. In
case of very low-risk interaction, regular monitoring
is suggested (see Table 2 and Additional File 1:
Table S8).
3. An estimation of psychotropic-related risk of re-
spiratory depression should systematically take into
account the following: (a) the intrinsic sedative pro-
prieties of psychotropic medications, their half-life
(higher risk for longer half-life), the dose, and the
occurrence of other aspects possibly impairing res-
piration (e.g., reduced motility, sialorrhea); (b) phar-
macokinetic interactions raising plasma levels of
sedative medications (e.g., lopinavir/ritonavir com-
bined with quetiapine) and pharmacodynamic inter-
actions (e.g., co-treatments with opioids); and (c)
pre-existing respiratory impairment (e.g., COPD)
and degree of COVID-19-related respiratory
depression.
4. Antipsychotic medications are at risk of worsening
respiratory function in people with COVID-19, par-
ticularly at high doses and when used in combin-
ation. Antipsychotics with highly sedative profiles
should be avoided or used short term.
5. The risk of respiratory impairment associated with
benzodiazepines in the general population is
debated, but might be particularly relevant in
elderly patients with COVID-19 and pre-existing
comorbidities (e.g., COPD). Benzodiazepines should
be avoided or used short term (e.g., control of acute
agitation), preferring those with shorter half-life
(e.g., etizolam, oxazepam, lorazepam). Although an-
tidepressants are generally considered safe in terms
of respiratory impairment, caution is advised as data
are controversial.
6. An estimation of psychotropic-related risk of car-
diovascular events should systematically take into
account the following: (a) the intrinsic QTc-
prolonging proprieties of psychotropic medications,
their cumulative dose, and use in combination; (b)
pharmacokinetic interactions possibly raising
plasma levels of QTc-prolonging medications and
pharmacodynamic interactions (e.g., co-treatments
with antivirals, chloroquine, hydroxychloroquine,
and opioids); and (c) pre-existing cardiovascular
conditions (in particular, ischemic heart disease)
and COVID-19-related cardiovascular conditions.
7. For interactions with low-to-moderate risk of QTc
prolongation, an adjustment towards a lower dose
of one or both medications is generally required,
along with regular electrocardiogram monitoring. In
case these interactions add up with other risk fac-
tors for QTc prolongation (e.g., cardiovascular co-
morbidities, electrolyte abnormalities), medications
at risk should be avoided, or withdrawn, or
switched to safer medications, as clinically
appropriate.
8. Antipsychotics, benzodiazepines, and some mood
stabilizers may be associated with an increased risk
of secondary infections in people with COVID-19,
and possibly with an unfavorable course of systemic
infections. The risk is likely to be particularly rele-
vant for clozapine, carbamazepine, and oxcarbaze-
pine. Regular monitoring is therefore indicated.
9. In people with COVID-19, both antipsychotics and
antidepressants might increase the risk of thrombo-
embolism, particularly in the elderly. In people with
COVID-19 taking heparin prophylaxis, antidepres-
sants might increase the risk of bleeding, with a
higher risk for serotoninergic agents (i.e., SSRIs and
SNRIs), especially in elderly patients. Regular moni-
toring is indicated. In case there are additional risk
factors for bleeding (e.g., other coagulation abnor-
malities, old age, anticoagulant therapy, major sur-
gery), a dose adjustment or withdrawing the
medications at risk should considered, as clinically
appropriate.
10. In people with COVID-19 and known risk factors
for delirium (e.g., old age, dementia, multiple co-
morbidities), the use of agents with anticholinergic
properties (e.g., tricyclic antidepressants and parox-
etine), benzodiazepines (particularly midazolam),
and lithium should generally be avoided.
11. In patients with COVID-19 who are already in
treatment with psychotropic medications, an accur-
ate assessment of current psychiatric symptoms and
past psychiatric history is important in order to re-
view the need of continuing treatment and its dose.
12. In addition to psychotropic medications, and when
drug treatment is clinically inappropriate, clinicians
should carefully assess whether adequate supportive




The dramatic situation created by the COVID-19 pan-
demic requires rapid adjustments to the dynamic inter-
play between medical and psychiatric needs of patients.
This literature review explored a number of safety issues
relevant for the management of psychotropic
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medications in people with COVID-19 and informed the
discussion of a working group of clinical and research
experts.
In general, we found that all classes of psychotropic
medications have potentially relevant safety issues for
people with COVID-19. The magnitude of risk of indi-
vidual agents or classes of medications was unclear or
unreliable in most cases, considering the paucity of data,
and the relevant indirectness of populations considered.
Unavoidably, in clinical practice, the risk of unfavorable
outcomes needs to be carefully weighed on a case-by-
case basis, in light of a number of co-existing risk fac-
tors. It is therefore challenging to provide recommenda-
tions limited to specific clinical situations or single
medications. Moreover, although different safety issues
have been explored separately, they are actually broadly
overlapping (i.e., respiratory function might be impaired
by both the sedative effect of medications and the in-
creased risk for respiratory infections).
Although the working group selected a number of
safety issues to address, other principles of drug manage-
ment should not be overlooked. In particular, as acute
multifactorial hepatic and kidney injury has been de-
scribed in people with COVID-19 [109, 110], liver and
kidney functioning should be closely monitored. Possibly
hepatotoxic (e.g., valproate, carbamazepine, tricyclic an-
tidepressants) and nephrotoxic psychotropic medications
(e.g., lithium), as well as psychotropic medications exten-
sively metabolized by the liver (such as most of antide-
pressants, antipsychotics, and mood stabilizers) and
subject to renal excretion (e.g., lithium, gabapentin,
topiramate, pregabalin, and paliperidone), should be rou-
tinely revised in order to adjust the dose or withdraw
the medication in case of high clinical risk.
Practical recommendations were formulated in order
to support clinicians in the assessment and management
of the risk related to psychotropic medications. In many
cases, adjusting the dose of medical or psychotropic
medications is probably a satisfactory and pragmatic
safety measure. However, when the risk of severe ad-
verse events is relevant, withdrawing the medication or
switching to a safer one might be required. In any case,
an accurate assessment of current psychopathology is
key, considering that, for some patients, psychotropic
treatments are essential (e.g., long-standing maintenance
with antipsychotics or mood stabilizers) and should be
safeguarded, while, for some other patients, medications
can be decreased in dose or even withdrawn (consider-
ing for example that benzodiazepines and antidepres-
sants are frequently prescribed inappropriately) [111,
112], provided that good practices for managing with-
drawal risk are followed [56, 94]. As a general consider-
ation, the working group agreed that supportive
psychosocial interventions (even electronically delivered
and provided by non-specialist health-care providers)
[113–115] should not be neglected in order to mitigate
the emotional stress and pressure that can exacerbate
both psychiatric and medical conditions [116], and this
is particularly relevant when pharmacological interven-
tions are limited or unfeasible. Arguably, this set of sim-
ple recommendations can be easily applicable in clinical
practice, as no particular limitations emerged in terms of
costs, as well as values and preferences of patients and
key stakeholders (see Additional File 1: Table S9), and
the principles described are easily accessible not only for
psychiatrists, but also for other specialists directly in-
volved in the care of people with COVID-19.
Limitations
Several limitations should be acknowledged. Firstly, fol-
lowing the WHO Rapid Advice Guidelines for public
health emergencies [13], a simplified methodology was
employed for evidence gathering and aggregation, in-
cluding the lack of a review protocol, a simplified search
process (limitation to articles published in the last 10
years, no clear-cut predefined inclusion and exclusion
criteria), the lack of a formal assessment of the certainty
of evidence with the GRADE methodology, the lack of
external review of the process, and the lack of indica-
tions for a process of audit and feedback (see Additional
File 1: Table S10). Furthermore, the working group in-
cluded mostly psychiatrists and experts in research
methodology, while other potentially interested stake-
holders were not involved. Secondly, the working group
decided to give priority to safety issues of relevance for
both psychiatrists, infective disease doctors, and other
specialists, while the efficacy of psychotropic medica-
tions in people with severe medical illness was not
assessed. Thirdly, in many cases, the clinical relevance of
drug–drug interactions was difficult to ascertain, consid-
ering both the scarcity of data and the multitude of po-
tential co-occurring factors possibly influencing the
metabolism, distribution, and target action of medical
and psychotropic medications. Fourthly, all medical
treatments for COVID-19 are currently employed off-
label according to principles of compassionate use. The
list of medications included in this review cannot be
considered exhaustive, as it is possible that new treat-
ments will undergo research scrutiny and be employed
in clinical practice, as the field is rapidly evolving. In this
case, the working group will update the search of the
evidence and content of recommendations if needed.
Also, considering the global threat represented by
COVID-19 and the novelty of this condition, the search
for rapid solutions might lead to an uncontrolled use of
off-label medications [117]. This problem is likely to in-
volve also psychotropic medications, considering that
the use of standard treatments might be limited due to
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the underlying complex medical conditions. A final limita-
tion is that the role of psychosocial interventions in the
optimal management of psychotropic drugs was not for-
mally addressed with a dedicated search and discussion.
Conclusions
Currently, many patients with COVID-19 require treat-
ment with psychotropic medications, whose appropriate
management is particularly challenging in light of the
underlying medical condition and the high risk of drug–
drug interactions. Clinicians need to be vigilant when
initiating psychotropic agents in patients receiving med-
ical drugs for COVID-19. Similarly, when deciding to
prescribe experimental medical drugs in patients under
long-term psychopharmacological treatment, clinicians
need to be extremely cautious considering that medical
treatments for COVID-19 are still experimental and
their efficacy debated.
Hopefully, as clinical interventions can best be deliv-
ered when clear, evidence-based guidance is provided,
the pragmatic principles described here can favor an op-
timal management of psychotropic medicines for pa-
tients with COVID-19, aiming to address potentially
emerging psychopathology, maintain control of under-
lying psychiatric condition, mitigate the potentially ag-
gravating effects of psychological stress, and, in general,
manage the medical condition without worsening the
psychiatric condition and vice versa.
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